AIMD logo

AINOS INC

AIMDNASDAQ
🏆 #4964 by market capUS Equity
$0.82▼ $0.08 (−8.80%)
Market closed · at close
🔔
Track AIMD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 8.8%
7d▼ 8.8%
14d▼ 15.0%
30d▼ 34.7%
ytd▼ 50.2%
1y▼ 77.6%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
-87.7%
Declining
📊Gross Margin
78.8%
High
💵FCF Margin
1102.9%
Strong
⚖️P/S Ratio
440.2x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.82 – $0.82
52-Week Range
$0.78 – $3.88
Volume (shares)
367
Avg Volume (shares)
—
Shares Outstanding
7.4M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$124,157
Last Q Revenue
$152
P/E Ratio
—
P/S Ratio
440.2x
EPS (TTM)
$-2.53
Dividend Yield
—
Dilution (1yr)
−36.5%
AIMD logo

AINOS INC

AIMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$124K▲ +499.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-3767.2%▲ +2350.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$14M▲ +1.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −20.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.0M▼ −36.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$11M▼ −$2M YoY
StockOtter · stockotter.space

About AINOS INC

Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.